Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

Unregulated compounded GLP-1s are not the same as the legitimate medications that doctors prescribe for weight loss and chronic disease management.

The Trump administration plans to announce a deal with pharmaceutical companies to sell discounted weight-loss drugs through ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

BY NOW, YOUR news feed, your dinner table conversations, and your doctor’s office have been flooded with chatter about the ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

People eagerly awaiting weight-loss pills should keep in mind that they're unlikely to be much cheaper than the injectable versions of GLP-1s. While the format does away with the cost of needles, Novo ...

The Food and Drug Administration approved Novo Nordisk’s NOVO.B-0.26%decrease; red down pointing triangle oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults ...

A new oral drug stands to become the first prescription pill specifically designed to regrow hair in both women and men. If approved following current Phase 3 trials, it would be the first new ...